Co-immunoprecipitation-mass spectrometry (Co-IP-MS) and immunoprecipitation-mass spectrometry (IP-MS) both recover an endogenous bait with an antibody and identify proteins by LC-MS/MS. Co-IP-MS asks which proteins share a complex with that bait. IP-MS asks whether the antibody recovers the bait itself, and which proteins co-purify under those conditions. Both need documented antibody specificity, Input and IgG or bead controls, and measurable bait enrichment before a partner list is credible. They do not prove binary direct binding (Hein et al. 2015). Prefer Co-IP-MS for endogenous interactor discovery when the antibody works in IP. Prefer IP-MS when bait recovery or antibody qualification is the first claim. Prefer AP-MS when tagging is acceptable and antibody performance is the bottleneck.

Researchers who already have a named bait, antibody or tag status, and a written interaction claim can also review the MtoZ Biolabs Protein-Protein Interaction Analysis and IP-Mass Spectrometry Service for project-specific workflow feasibility.

What IP-MS, Co-IP-MS, and AP-MS Are Designed to Answer

These names are often used as if they were one enrichment. They are not. All three couple affinity capture to LC-MS/MS, but the scientific sentence they can support is different.

IP-MS asks whether an antibody can enrich a bait from a complex sample and which proteins co-purify under those conditions. It is the right first workflow when the bait is endogenous, when antibody performance must be evaluated for MS, or when the immediate claim is bait recovery rather than an interactome.

Co-IP-MS asks which proteins associate with an endogenous bait under physiological or near-physiological conditions. The capture handle is still a specific antibody. The output is a candidate interactor list that still requires controls and orthogonal tests. Identification depth in a Co-IP-style eluate is typically hundreds to about a thousand proteins, depending on the sample, not a proteome-wide census.

AP-MS asks which proteins associate with an affinity-tagged bait expressed in a defined system. The tag replaces target-specific antibody dependence and supports matched purification across mutants or conditions. Tag design, expression level, and empty-tag controls then dominate interpretation.

Pull-down-MS sits in the same decision space but uses an immobilized recombinant bait. It can test reconstituted retention under controlled chemistry. It does not represent endogenous complex architecture and does not prove a direct cellular contact. That contrast is developed in Endogenous IP-MS vs. Tagged Pull-Down MS. Tagged versus antibody interactome choice is also compared in AP-MS vs IP-MS: How to Choose the Right Interactome Workflow.

IP-MS qualifies bait recovery; Co-IP-MS ranks candidate partners of an endogenous bait; AP-MS maps a tagged bait. None of the three proves binary direct binding.

Antibody Specificity, Input and IgG Controls, and Enrichment Efficiency

Antibody specificity is the main controllable variable in IP-MS and Co-IP-MS. An antibody can work in Western blot or immunofluorescence and still fail under IP conditions because epitope accessibility, lysis chemistry, and bead handling differ. Specificity here means the antibody recovers the intended bait relative to Input and does not pull a dominant off-target that then looks like a partner.

Input is not optional decoration. An Input aliquot taken before capture shows whether the bait was present at a detectable level and provides a baseline intensity for enrichment calculations. Without Input, a missing bait in the eluate can be misread as a failed interaction rather than a failed IP.

IgG or bead controls answer a different question. Isotype-matched IgG estimates antibody-driven background. Bead-only controls estimate resin binders under the same lysis and wash. Empty-tag lines belong to AP-MS, not to antibody IP. A contaminant catalog such as the CRAPome is a prior on control frequency, not a substitute for the current Input and IgG pair (Mellacheruvu et al. 2013).

Enrichment efficiency is bait-first. If bait peptides are weak or absent versus Input, partner names in the same file are not a credible Co-IP-MS result. Relative intensity can compare the same protein across Input, IgG, and bait IP. It does not rank different proteins as tighter binders.

Check	Pass criterion	Common failure
Antibody specificity	Bait recovered versus Input; off-targets do not dominate	Western-only antibody used as if it were IP-grade
Input	Bait detectable before capture	Eluate interpreted with no starting abundance
IgG or bead control	Same handling depth as bait IP	Control omitted or washed unlike the bait IP
Enrichment efficiency	Bait higher in bait IP than in IgG and Input-adjusted background	Weak bait, long partner list treated as interactome
MS credibility	Enrichment rule declared before ranking	Presence-or-absence calling on unreplicated IPs

Protocol-level capture and wash decisions are covered in IP-MS Protocol: From Antibody Capture to LC-MS/MS.

Figure 1. IP-MS and Co-IP-MS share antibody capture of an endogenous bait; AP-MS replaces the antibody with an affinity tag.

How to Read MS Credibility After Enrichment

Identification of a protein in an IP, Co-IP, or AP eluate is not a confidence call. Ranking requires bait recovery, handle-matched controls, and a declared enrichment rule. Probabilistic scoring such as SAINT uses bait versus control counts to assign a probability that a prey is specifically co-purified (Choi et al. 2011). Those scores still operate on enrichment tables.

A practical credibility sequence is:

1. Confirm the bait in Input and in the bait eluate.
2. Compare bait intensity with IgG or empty-tag controls processed identically.
3. Remove proteins that fail identification or quantitation QC.
4. Rank remaining names against the matched control, not against an unmatched public list alone.
5. Keep a shortlist for reciprocal capture or a defined-pair assay.

After filtering, a protein-level value can support a relative statement: protein B is enriched with bait A versus the matched control inside this capture recipe. Peptide support, Input abundance, IgG frequency, and wash conditions belong next to that statement. Ordinary tables should not infer a diagnostic interaction or transfer a partner list from one lysis buffer to another study as a conserved complex.

Pathway maps interpret a shortlist. They do not repair a missing Input, a Western-only antibody, or a failed bait enrichment. Mixed enrichment-MS projects can be reviewed under the MS-Based Protein-Protein Interaction Analysis Service.

Figure 2. MS credibility starts at antibody specificity, Input, and enrichment efficiency, not at the length of the protein table.

Judgment Criteria: Which Workflow Fits

Decision factor	IP-MS	Co-IP-MS	AP-MS
Typical bait	Endogenous protein	Endogenous protein	Tagged protein
Capture handle	Target-specific antibody	Target-specific antibody	Affinity tag
Primary claim	Bait recovery and associated proteins	Endogenous partner discovery	Tagged interactome or construct series
Needs IP-competent antibody	Yes	Yes	No
Core controls	Input, IgG, bead-only	Input, IgG, bead-only	Input, empty-tag, bead-only
Main risk	Poor antibody performance	Background binders after weak capture	Tag or overexpression artifacts

Prefer IP-MS when the first question is whether the antibody recovers the bait under MS-compatible conditions. Prefer Co-IP-MS when that antibody already works and the question is which endogenous proteins co-enrich with the bait. Prefer AP-MS when tagging is acceptable and antibody performance is uncertain, or when many constructs must share one purification chemistry.

Reassess Co-IP-MS when Input shows the bait but the eluate does not, when IgG recovers the same dominant names, or when wash chemistry erases known positive partners. Reassess AP-MS when the sample cannot be tagged, or when the tag changes localization or function.

For screening-level method choice among antibody, tag, pull-down, and proximity labeling routes, see Measuring Protein-Protein Interactions. Immobilized bait follow-up is scoped through the GST Pull Down Assay Service.

Figure 3. Workflow fit follows the written claim and antibody or tag readiness, not the shared use of LC-MS/MS.

Common Biases and Result Boundaries

IP-MS and Co-IP-MS tend to overcall proteins that bind antibody constant regions, proteins that stick to beads, and proteins related to antibody cross-reactivity. Weak enrichment efficiency creates long lists that look like discovery but track contaminants. AP-MS tends to overcall tag binders, overexpression-recruited proteins, and partners stabilized by non-native localization.

A later requery of the same raw files can add peptides that the first search missed. It cannot repair a design that omitted Input or processed IgG unlike the bait IP. Orthogonal confirmation by reciprocal IP, a defined-pair pull-down, or proximity labeling is still required if the claim moves from co-recovery to engagement.

An IP-MS or Co-IP-MS table supports candidate co-recovery under Input and IgG controls, not a certified binary interactome.

Once the claim, antibody or tag status, Input and IgG plan, and expected MS output are defined, the project can be scoped as IP-MS, Co-IP-MS, or AP-MS. Researchers can review the MtoZ Biolabs IP-Mass Spectrometry Service and MS-Based Protein-Protein Interaction Analysis Service for sample evaluation and workflow planning.

Frequently Asked Questions

1. Is IP-MS the same as Co-IP-MS?

They overlap in the laboratory but not in project emphasis. IP-MS focuses on antibody-based bait recovery and is often used to qualify the antibody. Co-IP-MS emphasizes discovery of endogenous proteins recovered with that bait.

2. Why is an Input control required for Co-IP-MS?

Input shows that the bait was present before capture and provides a baseline for enrichment. Without Input, a weak eluate can be misread as biology rather than failed immunoprecipitation.

3. When should I choose AP-MS instead of Co-IP-MS?

Choose AP-MS when tagging is acceptable and antibody performance is uncertain, or when matched purification across many constructs is required. Choose Co-IP-MS when endogenous context is essential and an IP-competent antibody is available.

4. Does stronger bait intensity mean a more credible interactome?

It means enrichment efficiency is better, which is required for interpretation. It does not by itself make every co-purified name a partner. IgG and bead controls still decide background.

5. Can MS alone prove a protein-protein interaction?

No. Enrichment MS identifies candidates based on co-purification. Direct-binding or functional claims need orthogonal assays and a control design that matches the capture handle.

Reference

1. M.Y. Hein, N.C. Hubner, I. Poser, J. Cox, N. Nagaraj, Y. Toyoda, I.A. Gak, I. Weisswange, J. Mansfeld, F. Buchholz, et al. (2015). A human interactome in three quantitative dimensions organized by stoichiometries and abundances. Cell, 163, 712-723. https://doi.org/10.1016/j.cell.2015.09.053
2. H. Choi, B. Larsen, Z.Y. Lin, A. Breitkreutz, D. Mellacheruvu, D. Fermin, Z.S. Qin, M. Tyers, A.C. Gingras, A.I. Nesvizhskii (2011). SAINT: probabilistic scoring of affinity purification-mass spectrometry data. Nat. Methods, 8, 70-73. https://doi.org/10.1038/nmeth.1541
3. D. Mellacheruvu, Z. Wright, A.L. Couzens, J.P. Lambert, N.A. St-Denis, T. Li, Y.V. Miteva, S. Hauri, M.E. Sardiu, T.Y. Low, et al. (2013). The CRAPome: a contaminant repository for affinity purification-mass spectrometry data. Nat. Methods, 10, 730-736. https://doi.org/10.1038/nmeth.2557